Dear Editor, Progressive multifocal leukoencephalopathy (PML) results from productive infection of glial cells by John Cunningham polyomavirus (JCV), facilitated by immune deficiency [1] . We report three cases of PML in HIV-negative patients who had been treated with rituximab (their main clinical features are summarized in Table 1 ). . Due to occurrence of infusion reactions (fever, chills, and lumbar pain), the last two doses were not administered. As only a partial response was achieved, the patient received eight courses of P-VMyBEC (September-October 2004). On December 2004, the patient developed paraplegia. Brain MRI and computed tomography showed multiple areas of subcortical demyelination. Despite JCV DNA testing negative in cerebrospinal fluid, due to the low sensitivity of this assay in HIV-negative patients [2] , he was finally diagnosed as probable PML, according to consensus terminology [3] . Unfortunately, the patient died in December 2004 before a stereotactic brain biopsy could be performed, and no necropsy was carried out.
PML occurs uncommonly in HIV-negative patients with lymphoprolipherative disorders, and it has been rarely reported during rituximab therapy [4] [5] [6] . The causal involvement of antiblastic therapies (i.e., purine analogs) in PML is not conclusive [1] , and the possible contribution of drugs other than rituximab to PML occurrence in our cases cannot be ruled out. However, case 1 developed PML while in complete remission and free from drug treatments (other than rituximab) since 18 months, making causality highly suspected.
Although immunodeficiency is recognized as a necessary condition for PML development, the mechanism by which JCV crosses the blood-brain barrier (BBB) remains uncertain. Serotonin receptor 2A (5-HT2AR) seems to be involved in JCV internalization into glial cells and some serotonin receptor antagonists (i.e., risperidone, mirtazapine) have been proposed as agents potentially blocking JCV entry [7, 8] . Two of the present cases received mirtazapine and/or risperidone as a tentative salvage therapy, but these drugs did not provide appreciable benefits. Of note, case 2 showed a delay in the progression of the primary lesion, but new focal lesions developed concomitantly. Consistently with recent investigations [9, 10] , the unfavorable outcome in our patients suggests that JCV might use alternative gates, besides 5-HT2AR, to cross the BBB.
In conclusion, the present cases support the hypothesis that exposure to rituximab may be an independent risk factor for the development of PML. Moreover, 5-HT2AR antagonists were ineffective in two of our cases, thus pointing out the need for more suitable therapeutic options. of the same lesion depicted a central core of hypointensity surrounded by a rim of high signal intensity suggesting a demyelinating lesion probably due to PML. Nine months later, the left frontal lesion showed a slight size reduction with atrophic feature of involved cerebral gyri (e). Nevertheless, similar white matter lesions involving also the subcortical "U" fibers with "scalloped" appearance developed in the left temporal and parietal lobes (f). White matter lesions progressively became multiple and confluent, affecting asymmetrically both cerebral hemispheres as shown in axial FLAIR images obtained 12 months later (g-h)
